Tristel PLC (LON:TSTL) has secured regulatory approval in India for its Duo ULT, Duo OPH and Duo EVE, disinfectant products.
The products have been approved for the decontamination of semi-critical medical devices by India's Medical Device & Diagnostics Division, Central Drugs Standard Control Organisation (CDSCO).
Duo ULT is intended for use on invasive ultrasound probes; Duo OPH is intended for use on ophthalmic instruments, and Duo EVE is intended for use on non-invasive medical devices such as colposcopes and non-porous surfaces of medical equipment used in women’s health.
“The three Duo products provide Indian hospitals with an affordable and easy-to-use high-level disinfection method for medical devices used in ultrasound, ophthalmology, and gynaecology. Infection prevention experts within India acknowledge the need for disinfection technologies that will enable hospitals to raise their decontamination standards. Combining these latest approvals with those previously gained gives us a broad product offering for the Indian market,” Paul Swinney, the chief executive officer of Tristel said in a statement.
"We can now press on with developing our commercial plan for India. We have initiated discussions with various potential partners for distribution of the products,” he added.